Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Inclusion Criteria

• •Recurrent or metastatic TNBC patients;
• •TNBC defined by immunohistochemistry as ER\<1%, PR\<1%, Her2=0\~1+, or 2+ while HER2 Fish test shows no amplification；
• •Previous received no or only first line chemotherapy treatment for recurrent or metastatic TNBC；When the time between cancer metastasis and the end of adjuvant chemotherapy exceeds 1 year, the systemic chemotherapy for metastasis treatment is recorded as first-line treatment; When less than 1year, the systemic chemotherapy for metastasis treatment is recorded as second-line treatment；
• •ages 18 to 75 years at the time of signing the informed consent form (ICF);
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
• •expected survival of ≥3 months; at least one measurable lesion per RECIST (version1.1);
• •acceptable renal and liver function;